31
Participants
Start Date
October 15, 2018
Primary Completion Date
August 24, 2021
Study Completion Date
August 24, 2021
Nitazoxanide
One 500 mg tablet twice daily with food for 56 consecutive doses
Placebo
One tablet twice daily with food for 56 consecutive doses
University of Michigan - Infectious Disease Clinic at Taubman Center, Ann Arbor
Northwestern University - Comprehensive Transplant Center, Chicago
University of Kansas Medical Center - Infectious Diseases, Kansas City
Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore
University of Michigan School of Public Health - Epidemiology, Ann Arbor
University of Nebraska Medical Center - Infectious Diseases, Omaha
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati
University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh
Children's Hospital of Pittsburgh of UPMC - Pediatric Infectious Diseases, Pittsburgh
University of Texas Southwestern Medical Center - Internal Medicine Subspecialties Clinic, Dallas
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Diseases, Seattle
University of Washington - Medicine, Seattle
National Institute of Allergy and Infectious Diseases (NIAID)
NIH